Skip to main content
SpringerLink
Log in

Tumorerkrankungen und Hormone

  • Chapter
  • First Online:
Klinische Endokrinologie für Frauenärzte

  • 178 Accesses

Zusammenfassung

Tumorerkrankungen sind häufig hormonabhängig. Hormone, reproduktive und metabolische Faktoren sind für Entstehung, Verlauf und Therapie der Erkrankungen von großer Bedeutung. Darüber hinaus gibt es Malignomerkrankungen, bei denen zwar keine endokrinen Therapien eingesetzt werden, endokrine Interventionen aber die Entstehung und den Verlauf der Erkrankungen beeinflussen. Eine Reihe von Tumoren produziert Hormone, die klinische Symptome verursachen können. Für Frauenärzte sind insbesondere Kenntnisse zu den hormonabhängigen und hormonproduzierenden gynäkologischen Tumoren relevant. Hervorzuheben ist hier das Endometriumkarzinom, bei dessen Entstehung Hormone und metabolische Faktoren starke Risikofaktoren sind. Auch den Verlauf der Erkrankung können sie beeinflussen. Antihormonelle Therapiestrategien werden bei metastasierten Erkrankungen eingesetzt. Reproduktive Faktoren und Hormone spielen als Risikofaktoren beim Ovarialkarzinom eine erhebliche Bedeutung. In der Therapie sind sie allerdings weniger relevant. Hormonproduzierende gynäkologische Malignome sind selten. Die klinische Manifestation kann allerdings besonders eindrucksvoll sein, wie z. B. bei androgenproduzierenden Ovarialtumoren. In diesem Kapitel werden Grundlagen und klinische Aspekte der Beziehung zwischen Endokrinium und Tumorwachstum dargelegt. Zur Diagnostik, Therapie und Nachsorge der Tumorerkrankungen wird auf die existierenden S3-Leitlinien des Onkologischen Leitlinienprogramms verwiesen (Leitlinienprogramm Onkologie). Benignen Erkrankungen und malignen Tumoren der Brustdrüse ist in diesem Buch ein gesondertes Kapitel gewidmet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L (1989) Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44:833–839

    Article  CAS  PubMed  Google Scholar 

  • Ali AT (2014) Reproductive factors and the risk of endometrial cancer. Int J Gynecol Cancer 24(3):384–393

    Article  PubMed  Google Scholar 

  • Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R, Lund E et al (2010) Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 172:1394–1403. https://www.ncbi.nlm.nih.gov/pubmed/20961969. Zugegriffen am 21.01.2022

  • Barry JA, Azizia MM, Hardiman PJ (2014) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 20(5):748–758

    Article  PubMed  PubMed Central  Google Scholar 

  • Beattie CW, Ronan SG, Amoss MS (1991) Estrogens influence the natural history of Sinclair swine cutaneous melanoma. Cancer Res 51:2025–2028

    CAS  PubMed  Google Scholar 

  • Beral V, Ramcharan S, Faris R (1977) Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 36:804–809

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Beral V, Bull D, Reeves G (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365:1543–1551

    Article  PubMed  Google Scholar 

  • Birkhaeuser M, Boettcher B, Germeyer A, Hadji P, Imthurn B, Mueck AO, Neulen J, Stute P, Thaler C, Wiegratz I, Wildt L. Gestagene und Meningeome – gibt es einen Zusammenhang?, FRAUENARZT 2/2022, S 105–106

    Google Scholar 

  • Bork K, Brauninger W (1986) Prior pregnancy and melanoma survival. Arch Dermatol 122:1097

    Article  CAS  PubMed  Google Scholar 

  • Bosetti C, Bravi F, Negri E, La Vecchia C (2009) Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 15(5):489–498

    Article  PubMed  Google Scholar 

  • Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947

    Article  PubMed  PubMed Central  Google Scholar 

  • Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Ovarian Cancer Association Consortium (2020) Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol 158(3):702–709

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Burchardt NA, Shafrir AL, Kaaks R, Tworoger SS, Fortner RT (2021) Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947–1964: the Nurses’ Health Study II, a prospective cohort study. Eur J Epidemiol 36(8):827–839

    Article  CAS  PubMed  Google Scholar 

  • Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS (2012) Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 21(1):20–38

    Article  CAS  Google Scholar 

  • Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O’Sullivan MJ, Ockene JK, Chen C, Hubbell FA (2009) Women’s Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374(9697):1243–1251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chlebowski RT, Anderson GL, Manson JE et al (2010) Lung cancer among postmenopausal women treated with estrogen alone in the women’s health initiative randomized trial. J Natl Cancer Inst 102(18):1413–1421

    Article  PubMed  PubMed Central  Google Scholar 

  • Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK et al (2015) Continuous combined estrogen plus progestin and endometrial cancer: the women’s health initiative randomized trial. J Natl Cancer Inst 108:djv350

    Article  PubMed  PubMed Central  Google Scholar 

  • Collaborative Group on Epidemiological Studies in Endometrial cancer (2015) Endometrial cancer and oral contraceptives: an individual paricipant meta-analysis of 27.276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol 16:1061–1070

    Article  Google Scholar 

  • Collaborative group on epidemiological studies of ovarian cancer (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet 371:303–314

    Article  Google Scholar 

  • Cortessis VK et al (2017) Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol 130(6):1226–1236

    Article  PubMed  Google Scholar 

  • Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG (2010) Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 19:3119–3130

    Article  CAS  Google Scholar 

  • DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E et al (2008) Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 26:4151–4159

    Article  PubMed  PubMed Central  Google Scholar 

  • Diaz LC, Das Gupta TK, Beattie CW (1986) Effects of gonadal steroids on melanocytes in developing hamsters. Pediatr Dermatol 3:247–256

    Article  CAS  PubMed  Google Scholar 

  • Dobbins M, Decorby K, Choi BC (2013) The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013:680536

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A et al (2009) Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 127:442–451

    Article  Google Scholar 

  • Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier F, Chabbert-Buffet N, Boeing H, Schütze M, Trichopoulou A, Trichopoulos D, Lagiou P, Palli D, Krogh V, Tumino R, Vineis P, Mattiello A, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PH, Dumeaux V, Redondo ML, Duell E, Sanchez-Cantalejo E, Arriola L, Chirlaque ML, Ardanaz E, Manjer J, Borgquist S, Lukanova A, Lundin E, Khaw KT, Wareham N, Key T, Chajes V, Rinaldi S, Slimani N, Mouw T, Gallo V, Riboli E (2010) Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 127(2):442–451. https://doi.org/10.1002/ijc.25050

    Article  CAS  PubMed  Google Scholar 

  • Endometriumkarzinom Langversion 2.0, Mai 2021, AWMF-Registernummer: 032/034-OL. https://www.leitlinienprogrammonkologie.de/leitlinien/endometriumkarzinom/. Zugriff am 04.02.2022

  • Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35:2402–2411

    Article  PubMed  PubMed Central  Google Scholar 

  • Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S, Seifert W et al (2008) Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol 112:653–659

    Article  PubMed  Google Scholar 

  • European Association for the Study of the Liver (EASL) (2016) EASL Clinical practice guidelines on the management of benign liver tumours. J Hepatol 65(2):386–398

    Article  Google Scholar 

  • Eysbouts YK, Bulten J, Ottevanger PB, Thomas CM, Ten Kate-Booij MJ, van Herwaarden AE, Siebers AG, Sweep FC, Massuger LF (2016) Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. Gynecol Oncol 140:70–75

    Article  CAS  PubMed  Google Scholar 

  • Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM, Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group (2010) Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control 21(12):2303–2308

    Article  PubMed  Google Scholar 

  • Feucht KA, Walker MJ, Das Gupta TK, Beattie CW (1988) Effect of 17 beta-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice. Cancer Res 48:7093–7101

    CAS  PubMed  Google Scholar 

  • Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107(1):103–111. https://doi.org/10.1007/s10549-007-9523-x. Epub 2007 Feb 27. Erratum in: Breast Cancer Res Treat. 2008;107(2):307-8. PMID: 17333341; PMCID: PMC2211383

    Article  CAS  PubMed  Google Scholar 

  • Fournier A, Dossus L, Mesrine S, Vilier A, Boutron-Ruault MC, Clavel-Chapelon F et al (2014) Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol 180:508–517

    Article  PubMed  Google Scholar 

  • Goncalves D, Leite JP, Silva R, Pissarra AP, Caetano Oliveira R, Silva D (2020) Hepatic adenomatosis : a challenging liver disease. GE Port. J Gastroenterol 27:37–42

    Google Scholar 

  • Grin CM, Driscoll MS, Grant-Kels JM (1998) The relationship of pregnancy, hormones, and melanoma. Semin Cutan Med Surg 17:167–171

    Article  CAS  PubMed  Google Scholar 

  • Guan HB, Wu QJ, Gong TT, Lin B, Wang YL, Liu CX (2013) Parity and risk of colorectal cancer: a dose-response meta-analysis of prospective studies. PLoS One 8(9):e75279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Haring MPD, Gouw ASH, de Haas RJ, Cuperus FJC, de Jong KP, de Meijer VE (2019) The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: a retrospective cohort study. Liver Int 39(5):905–913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Harris HR, Terry KL (2016) Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract 2:14

    Article  PubMed  PubMed Central  Google Scholar 

  • Hartge P, Tucker MA, Shields JA, Augsburger J, Hoover RN, Fraumeni JF (1989) Case-control study of female hormones and eye melanoma. Cancer Res 49:4622–4625

    CAS  PubMed  Google Scholar 

  • Hemmingsen CH, Kjaer SK, Bennetsen AKK et al (2021) The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer. Gynecol Oncol 162(2):469–474

    Article  PubMed  Google Scholar 

  • Holly EA, Weiss NS, Liff JM (1983) Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 70:827–831

    CAS  PubMed  Google Scholar 

  • Holly et al (1984) ist die Literaturstelle: Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 1983;70:827–31

    Google Scholar 

  • Hsu LH, Chu NM, Kao SH (2017) Estrogen, estrogen receptor and lung cancer. Int J Mol Sci 18(8):1713. Published 2017 Aug 5. https://doi.org/10.3390/ijms18081713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huang Y, Cai X, Qiu M, Chen P, Tang H, Hu Y et al (2014) Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57:2261–2269

    Article  CAS  PubMed  Google Scholar 

  • Huber D, Seitz S, Kast K et al (2020) Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet 301(4):875–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hui P, Baergen R, Cheung A, Fukunaga M, Gersell D, Lage J, Ronnett B, Sebire N, Wells M (2014) Gestational trophoblastic disease. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH (Hrsg) WHO classification of tumours of female reproductive organs. IARC, Lyon, S 158–167

    Google Scholar 

  • IARC monographs on the evaluation of carcinogenic risks to humans, 72, hormonal contraception and post-menopausal hormonal therapy. WHO, IARC, Lyon (1999). https://monographs.iarc.fr/wp-content/uploads/2018/06/mono72.pdf. Zugegriffen am 21.01.2022

  • Ignatov A, Ortmann O (2020) Endocrine risk factors of endometrial cancer: polycystic ovary syndrome, oral contraceptives, infertility, tamoxifen. Cancers (Basel) 12(7):1766

    Article  CAS  PubMed  Google Scholar 

  • International collaboration of epidemiological studies of cervical cancer (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609–1621

    Article  Google Scholar 

  • Iversen L et al (2017) Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol 216(6):580.e1–580.e9. https://doi.org/10.1016/j.ajog.2017.02.002

    Article  CAS  PubMed  Google Scholar 

  • Jareid M, Thalabard JC, Aarflot M et al (2018) Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol 149(1):127–132

    Article  CAS  PubMed  Google Scholar 

  • Jensen A, Sharif H, Ferderiksen K, Kjær SK (2009) Use of fertility drugs and risk of ovarian cancer: Danish population bases cohort study. BMJ 338:b249. https://doi.org/10.1136/bmj.b249

    Article  PubMed  PubMed Central  Google Scholar 

  • Kanda N, Watanabe S (2001) 17 beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J Invest Dermatol 117:274–283

    Article  CAS  PubMed  Google Scholar 

  • Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Cancer Genome Atlas Research Network; Nature 497(7447):67–73

    Google Scholar 

  • Karageorgi S, Hankinson SE, Kraft P, De Vivo I (2009) Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976–2004. Int J Cancer 126:208–216

    Article  Google Scholar 

  • Keck C, Tempfer C, Knobloch C, Breckwoldt M (2002) Hormone replacement therapy in women with malignant melanoma. Geburtshilfe Frauenheilkd 62(10):958–961

    Article  Google Scholar 

  • Kie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N (1991) Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet 37:653–655

    Google Scholar 

  • Krebs in Deutschland für 2017/18, Gemeinsame Publikation des Zentrums für Krebsregisterdaten und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., 13. Ausgabe, Robert-Koch-Institut, Berlin 2021

    Google Scholar 

  • Lederman JS, Lew RA, Koh HK, Sober AJ (1985) Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. J Natl Cancer Inst 74:981–985

    CAS  PubMed  Google Scholar 

  • Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). https://www.leitlinienprogramm-onkologie.de/home/. Zugegriffen am 04.02.2022

  • Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom Langversion 2.0, Mai 2021, AWMF-Registernummer: 032/034-OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/. Zugegriffen am 04.02.2022

  • Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Endometriumkarzinom, Langversion 2.0, 2022, AWMFRegisternummer: 032/034-OL. https://www.leitlinienprogrammonkologie.de/leitlinien/endometriumkarzinom/. Zugegriffen am 09.08.2023

  • Liao C, Zhang D, Mungo C, Andrew Tompkins D, Zeidan AM (2014) Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol 135:163–171

    Article  PubMed  PubMed Central  Google Scholar 

  • Lin KJ, Cheung WY, Lai JY, Giovannucci EL (2012) The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130(2):419–430

    Article  CAS  PubMed  Google Scholar 

  • LiverTox: clinical and research information on drug-induced liver injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda; 2012–. Estrogens and oral contraceptives (2020). PMID: 31643857

    Google Scholar 

  • Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell-Danielsson K, Johansson ALV (2019) The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. Eur J Epidemiol 34(5):499–507

    Article  PubMed  PubMed Central  Google Scholar 

  • Luo J, Beresford S, Chen C, Chlebowski R, Garcia L, Kuller L et al (2014) Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer 111:1432–1439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Luo J et al (2017) Intentional weight loss and endometrial cancer risk. J Clin Oncol 35(11):1189–1193

    Article  PubMed  PubMed Central  Google Scholar 

  • Manson JE, Chlebowski RT, Stefanick ML et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310(13):1353–1368

    Article  CAS  PubMed  Google Scholar 

  • McMichael AJ, Potter JD (1980) Reproduction, endogenous and exogenous sex hormones and colon cancer: a review and hypothesis. J Natl Cancer Inst 65:1201–1207

    CAS  PubMed  Google Scholar 

  • Michels KA, Pfeiffer RM, Brinton LA, Trabert B (2018) Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol 4(4):516–521

    Article  PubMed  PubMed Central  Google Scholar 

  • Moors G, Poels H, Vandecaveye V, Roskams T, Verslype C (2021) Regression of multiple hepatocellular adenomas after cessation of oral contraceptive pills: a case report and review of the current literature. Acta Gastroenterol Belg 84(3):505–508

    Article  CAS  PubMed  Google Scholar 

  • Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø (2009) Hormone therapy and ovarian cancer. JAMA 302:298–305

    Article  PubMed  Google Scholar 

  • Mørch LS, Løkkegaard E, Andreasen AH, Kjær SK, Lidegaard Ø (2012) Hormone therapy and ovarian borderline tumors: a national cohort study. Cancer Causes Control 23(1):113–120

    Article  PubMed  Google Scholar 

  • Mørch LS, Lidegaard Ø, Keiding N, Løkkegaard E, Kjær SK (2016) The influence of hormone therapies on colon and rectal cancer. Eur J Epidemiol 31(5):481–489

    Article  PubMed  Google Scholar 

  • Mueck AD, Seeger H, Rabe T (2010) Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 17:R263–R271. https://doi.org/10.1677/ERC-10-0076

    Article  CAS  PubMed  Google Scholar 

  • Murphy N, Strickler HD, Stanczyk FZ, Xue X, Wassertheil-Smoller S, Rohan TE, Ho GY, Anderson GL, Potter JD, Gunter MJ (2015) A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. J Natl Cancer Inst 107(10):djv210

    Article  PubMed  PubMed Central  Google Scholar 

  • Murphy N, Xu L, Zervoudakis A, Xue X, Kabat G, Rohan TE, Wassertheil-Smoller S, O’Sullivan MJ, Thomson C, Messina C, Strickler HD, Gunter MJ (2017) Reproductive and menstrual factors and colorectal cancer incidence in the Women’s Health Initiative Observational Study. Br J Cancer 116(1):117–125

    Article  PubMed  Google Scholar 

  • Murugappan G, Li S, Lathi RB, Baker VL, Eisenberg ML (2019) Risk of cancer in infertile women: analysis of US claims data. Hum Reprod 34(5):894–902

    Article  PubMed  Google Scholar 

  • Nelson HD, Smith ME, Griffin JC, Fu R (2013) Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 158:604–614. https://www.ncbi.nlm.nih.gov/pubmed/23588749

    Article  PubMed  Google Scholar 

  • Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155(3):217–224

    Article  PubMed  Google Scholar 

  • Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Goodman MT, Carney ME, Matsuno RK, Lurie G, Moysich K, Kjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Hoyo C, Moorman P, Weber RP, Cramer DW, Vitonis AF, Bandera EV, Olson SH, Rodriguez-Rodriguez L, King M, Brinton LA, Yang H, Garcia-Closas M, Lissowska J, Anton-Culver H, Ziogas A, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Webb PM, Ovarian Cancer Association Consortium (2013) Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 20(2):251–262

    Article  PubMed  Google Scholar 

  • Pack GT, Scharnagel M (1951) The prognosis for malignant melanoma in the pregnant woman. Cancer 4:324–334

    Article  CAS  PubMed  Google Scholar 

  • Peri- and Postmenopause – Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3 Level, AWMF Registry No. 015-062, January 2020). http://www.awmf.org/leitlinien/detail/ll/015-062.html. Zugegriffen am 21.01.2022

  • Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy – long-term follow-up of a Swedish cohort. Int J Cancer 67:327–332

    Article  CAS  PubMed  Google Scholar 

  • Portet S, Banor T, Bousquet J, Simonneau A, Flores M, Ingrand P, Milin S, Karayan-Tapon L, Bataille B (2020) New insights into expression of hormonal receptors by meningiomas. World Neurosurg 140:e87–e96

    Article  PubMed  Google Scholar 

  • Proctor JW, Yamamura Y, Gaydos D, Mastromatteo W (1981) Further studies on endocrine factors and the growth and spread of B16 melanoma. Oncology 38:102–105

    Article  CAS  PubMed  Google Scholar 

  • Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D; KConFab Investigators; HEBON Investigators; GEMO Study Collaborators; EMBRACE Collaborators; Antoniou AC, Goldgar DE, Olopade OI, Chenevix-Trench G, Rebbeck TR, Huo D; CIMBA (2019) Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. Br J Cancer. 121(2):180–192. https://doi.org/10.1038/s41416-019-0492-8. Epub 2019 Jun 19.

  • Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J et al (2019) Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer 145(7):1719–1730

    Article  CAS  PubMed  Google Scholar 

  • Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578

    Article  PubMed  Google Scholar 

  • Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A, Oikonomou E, Pera G, Larrañaga N, Martinez-Garcia C, Ardanaz E, Quirós JR, Tormo MJ, Tjønneland A, Olsen A, Overvad K, Chang-Claude J, Linseisen J, Schulz M, Boeing H, van Gils CH, Bueno-de-Mesquita BH, Pala V, Palli D, Panico S, Tumino R, Vineis P, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC, Lundin E, Agren A, Berglund G, Manjer J, Kumle M, Lund E, Slimani N, Saracci R, Riboli E, Kaaks R (2007) Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomark Prev 16(1):23–29

    Article  CAS  Google Scholar 

  • Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT (1986) Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 293(6543):359–362

    Article  CAS  PubMed  Google Scholar 

  • Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331:771–776

    Article  CAS  PubMed  Google Scholar 

  • Roura E, Travier N, Waterboer T et al (2016) The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC cohort. PLoS One. https://doi.org/10.1371/journal.pone.0147029. Zugegriffen am 07.02.2022

  • S3-Leitlinie Kolorektales Karzinom: AWMF-Registernummer 021/007OL (2019)

    Google Scholar 

  • S3-Leitlinie Prävention, Diagnostik und Nachsorge des Lungenkarzinoms: AWMF-Registernummer 020/007OL (2018)

    Google Scholar 

  • Sanikini H, Muller DC, Sophiea M et al (2020) Anthropometric and reproductive factors and risk of esophageal and gastric cancer by subtype and subsite: results from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer 146(4):929–942

    Article  CAS  PubMed  Google Scholar 

  • Schleicher RL, Hitselberger MH, Beattie CW (1987) Inhibition of hamster melanoma growth by estrogen. Cancer Res 47:453–459

    CAS  PubMed  Google Scholar 

  • Schock H et al (2014) Early pregnancy sex steroids and maternal breast cancer: a nested case-control study. Cancer Res 74(23):6958–6967

    Article  PubMed  PubMed Central  Google Scholar 

  • Schrijver LH, Antoniou AC, Olsson H, Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study et al (2021) Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol 225(1):51.e1–51.e17

    Article  CAS  PubMed  Google Scholar 

  • Shaw HM, Milton GW, Farago G, McCarthy WH (1978) Endocrine influences on survival from malignant melanoma. Cancer 42:669–677

    Article  CAS  PubMed  Google Scholar 

  • Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ (2013) Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14(9):853–862. https://doi.org/10.1016/S1470-2045(13)70253-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Simon SR, Ershler WB (1985) Hormonal influences on growth of B16 murine melanoma. J Natl Cancer Inst 74:1085–1088

    CAS  PubMed  Google Scholar 

  • Skalkidou A, Sergentanis TN, Gialamas SP, Georgakis MK, Psaltopoulou T, Trivella M, Siristatidis CS, Evangelou E, Petridou E (2017) Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility. Cochrane Database Syst Rev 3(3):CD010931

    PubMed  Google Scholar 

  • Stidham KR, Johnson JL, Seigler HF (1994) Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 129:316–324

    Article  CAS  PubMed  Google Scholar 

  • Sun Q, Sun H, Cong L, Zheng Y, Wu N, Cong X (2020) Effects of exogenous hormones and reproductive factors on female melanoma: a meta-analysis. Clin Epidemiol 12:1183–1203

    Article  PubMed  PubMed Central  Google Scholar 

  • Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA (2020) Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers (Basel) 12(8):2195

    Article  CAS  PubMed  Google Scholar 

  • The 2017 hormone therapy position statement of the North American menopause Society. Menopause (2018) 25(11):1362–1387

    Google Scholar 

  • Titan AL, He H, Lui N, Liou D, Berry M, Shrager JB, Backhus LM (2020) The influence of hormone replacement therapy on lung cancer incidence and mortality. J Thorac Cardiovasc Surg 159(4):1546–1556.e4

    Article  PubMed  Google Scholar 

  • Travers RL, Sober AJ, Berwick M, Mihm MC, Barnhill RL, Duncan LM (1995) Increased thickness of pregnancy-associated melanoma. Br J Dermatol 132:876–883

    Article  CAS  PubMed  Google Scholar 

  • Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433

    Article  CAS  PubMed  Google Scholar 

  • Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjosé S, Shin HR, Sukvirach S, Lazcano-Ponce E, Ronco G, Rajkumar R, Qiao YL, Muñoz N, Franceschi S (2006) Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomark Prev 15:2148–2153

    Article  CAS  Google Scholar 

  • Vargiu V, Amar ID, Rosati A et al (2021) Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric 24(2):120–127

    Article  CAS  PubMed  Google Scholar 

  • Walker MJ, Chaudhuri PK, Das Gupta TK, Beattie CW (1980) Influence of host sex on the growth of human melanoma. Proc Soc Exp Biol Med 165:96–99

    Article  CAS  PubMed  Google Scholar 

  • Wang H, Wu X, Englund K, Masironi B, Eriksson H, Sahlin L (2001) Different expression of estrogen receptors alpha and beta in human myometrium and leiomyoma during the proliferative phase of the menstrual cycle and after GnRHa treatment. Gynecol Endocrinol 15(6):443–452

    Article  CAS  PubMed  Google Scholar 

  • Wernli KJ, Wang Y, Zheng Y, Potter JD, Newcomb PA (2009) The relationship between gravidity and parity and colorectal cancer risk. J Women's Health (Larchmt) 18(7):995–1001

    Article  Google Scholar 

  • Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136:1212–1220

    Article  CAS  PubMed  Google Scholar 

  • Williams C, DiLeo A, Niv Y, Gustafsson JÅ (2016) Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett 372(1):48–56

    Article  CAS  PubMed  Google Scholar 

  • Wu W, Yin ZH, Guan P, Ren YW, Zhou BS (2014) Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies. Asian Pac J Cancer Prev 15(3):1205–1210

    Article  PubMed  Google Scholar 

  • Yang HP, Cook LS, Weiderpass E, Adami HO, Anderson KE, Cai H, Cerhan JR, Clendenen TV, Felix AS, Friedenreich CM et al (2015) Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (e2c2). Br J Cancer 112:925–933

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yuk JS, Baek JC, Park JE, Jo HC, Park JK, Cho IA (2019) Incidence of gestational trophoblastic disease in South Korea: a longitudinal, population-based study. PeerJ 7:e6490

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Regensburg, Regensburg, Deutschland

    O. Ortmann & D. Huber

  2. Klinik für Frauenheilkunde, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Herne, Deutschland

    C. Tempfer

Authors
  1. O. Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Tempfer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Ortmann .

Editor information

Editors and Affiliations

  1. Abt. Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik Heidelberg, Heidelberg, Deutschland

    Thomas Strowitzki

  2. Universitätsfrauenklinik Regensburg, Regensburg, Deutschland

    Olaf Ortmann

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ortmann, O., Huber, D., Tempfer, C. (2024). Tumorerkrankungen und Hormone. In: Strowitzki, T., Ortmann, O. (eds) Klinische Endokrinologie für Frauenärzte. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-65517-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-65517-7_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-65516-0

  • Online ISBN: 978-3-662-65517-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation